Skip to main content

Table 3 MOG-IgG, MOG-IgG1, MOG-IgM, and MOG-IgA results from 21 samples

From: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

No MOG-IgG1 MOG-IgG MOG-IgM MOG-IgA Disease status
1 POS POS NEG NEG Relapse
2 POS POS NEG NEG Relapse
3A POS POS NEG NEG Relapse
3B POS POS NEG NEG Remission
4 POS POS NEG NEG Remission
5 POS POS NEG NEG Remission
6 POS POS NEG NEG Remission
7 POS POS NEG NEG Remission
8 POS POS NEG NEG Relapse
9A POS POS NEG NEG Relapse
9B n.d. POS NEG NEG Remission
10A POS POS NEG NEG Relapse
10B n.d. POS NEG NEG Remission
11 n.d. POS NEG NEG Relapse
12 n.d. POS NEG NEG Remission
13 n.d. POS NEG NEG Remission
14A n.d. POS 1:1000 POS 1:20 NEG Relapse
14B n.d. POS 1:100 POS 1:10 NEG Remission
15A n.d. POS NEG NEG Remission
15B n.d. POS NEG NEG Remission
16 POS POS n.d. n.d. Relapse
17 POS POS n.d. n.d. Relapse
18 POS POS n.d. n.d. Relapse
  1. MOG-IgG was determined using a commercial fixed CBA (cut-off 1:10). MOG-IgG1 was also present in 3/3 CSF samples from MOG-IgG1-seropositive patients (not shown). POS positive, NEG negative, n.d not done